Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlilumab + IMA950/poly-ICLC in LGG
NCT02924038Phase 1Terminated
- Sponsor
- Nicholas Butowski
- Start
- Apr 2017
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of varlilumab in glioma (2 arms), sponsored by Nicholas Butowski. Primary endpoints: Proportion of Participants Experiencing Regimen Limiting Toxicity up to 2 years, Mean Percentage of CD8+ T-cell Responses in Pre- and Post-vaccine PBMC up to 2 years and 1 more. Started Apr 2017; status: terminated.
02
Drugs
varlilumab
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02924038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924038.